{"url_path":"/sec/cnta/8-k/2026-06-24/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/1847903/0001193125-26-280337-index.html","accession_number":"0001193125-26-280337","cik":"0001847903","ticker":"CNTA","issuer_name":"Centessa Pharmaceuticals plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1847903/0001193125-26-280337-index.html","primary_entity_key":"0001847903","primary_entity_name":"Centessa Pharmaceuticals plc"},"word_count":368,"has_tables":true,"body_markdown":"8-K\n\n0001847903 false 0001847903 2026-06-24 2026-06-24 0001847903 cnta:OrdinarySharesNominalValue0.002PerShareMember 2026-06-24 2026-06-24 0001847903 dei:AdrMember 2026-06-24 2026-06-24\n\n \n\n \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\n \n\n \n\nFORM 8-K\n\n \n\n \n\nCURRENT REPORT\n\nPURSUANT TO SECTION 13 OR 15(d)\n\nOF THE SECURITIES EXCHANGE ACT OF 1934\n\nDate of Report (date of earliest event reported): June 24, 2026\n\n \n\n \n\nCENTESSA PHARMACEUTICALS PLC\n\n(Exact name of Registrant, as specified in its charter)\n\n \n\n \n\n \n\nEngland and Wales\n \n001-40445\n \n98-1612294\n\n(State or other jurisdiction\nof incorporation)\n \n\n(Commission\n\nFile Number)\n\n \n(I.R.S. Employer\nIdentification Number)\n\nMailing address:\n\n3rd Floor\n\n1 Ashley Road\n\nAltrincham\n\nCheshire WA14 2DT\n\nUnited Kingdom\n\n(Address of principal executive offices) (Zip code)\n\nRegistrant’s telephone number, including area code: +1 (617) 468-5770\n\nFormer name or address, if changed since last report:\n\n \n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):\n\n \n\n☐\n\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐\n\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐\n\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐\n\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\n\n \n\nTrading\nSymbol(s)\n\n \n\nName of each exchange\non which registered\n\nOrdinary shares, nominal value £0.002 per share\n \nCNTA\n \nThe Nasdaq Stock Market LLC*\n\nAmerican Depositary Shares, each representing one ordinary share, nominal value £0.002 per share\n \nCNTA\n \nThe Nasdaq Stock Market LLC\n\n \n\n*\n\nNot for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market, LLC.\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\nEmerging growth company ☒\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}